Enabling Cutting-Edge Technologies That Will Help Shape Our Future
2123 Frontiers uses our research, experts, and gatherings to take a systems approach to “enable” current cutting-edge technologies in science, engineering, medicine and technology.
Defining a frontier or breakthrough is no easy feat, but at its core, we believe these are “significant” advancements with the potential to create a positive impact on humanity. Honestly, some of them will work, and many may not. Some will be quick; some will take decades. The most important thing is to have the aspiration to change the trajectory of societal impact.
We believe this magic happens at the intersection of science, medicine, business, and engineering, driven by leaders who have the boldness, resilience, and persistence to push the envelope on new frontiers and drive breakthroughs!! Our platform brings together driven entrepreneurs, innovators, pioneers, and visionaries, all with a common purpose — “enabling” breakthroughs as we collectively push society’s frontiers.
Our Frontiers
Healthcare & Life Sciences
The pace of medical innovation continues to accelerate with new ideas being pursued. Scientists are focused on several major areas of unmet need from rare diseases (Huntington’s disease, sickle cell anemia) to neurological conditions (Alzheimer's, Parkinson's, Epilepsy) to oncology (pancreatic cancer, lung cancer, colorectal cancer) and metabolic health (diabetes, obesity, hormonal conditions).
Scientists have been making significant progress on many new tools and foundational capabilities e.g. gene editing, pharmacogenomics, personalized medicine, predictive analysis, novel biomarkers, implantable/wearable devices, tissue cell engineering. These new diagnostics, devices, drugs, and software/AI will allow us to better tackle some of the most impactful diseases in medicine.
We want to enable innovators, scientists, physicians, investors and entrepreneurs to accelerate the pace of medical innovation for humanity.
High Tech
Solutions that improve data structure, data architecture models, and data related technologies such as generative AI, large language models, cloud-native data, real time data processing are foundational.
Advancement in computation such as hardware advancement (quantum computing, semiconductors), software, and algorithms (high performance computing, quantum algorithms) are enabling the processing of larger amounts of data.
Spatial computing, Augmented reality (AR), Virtual reality (VR) and mixed reality is considered the next big paradigm shift in computing, enabling human-computer interaction to take place in the real world, in and around natural bodies and physical environments.
Innovations in robotics such as soft robotics, autonomous systems, human-robot interactions, bio-inspired robotics and AI and robotics integration have wide-ranging applications in a variety of industries such as healthcare, manufacturing, education.
To enable the secure implementation of technology, advances in cybersecurity tools such as zero trust architecture, next generation cloud workforce protection, password-less authentication, blockchain, quantum computing as well as ethical and legal guidelines must be put into place.
All these innovations will contribute to transformation in every industry and bringing us closer to a reality once only imagined!
Company Spotlight: Reverb Therapeutics Update
Overview: Reverb Therapeutics continues to advance its mission of developing bispecific antibodies using the unique Amplify® platform to intelligently reshape the body's immune signals. Their lead program, AMP01, is a next-generation anti-PD-1 Plus bispecific designed to redirect endogenous IL-15 to PD-1+ cells. Over the past few months, the AMP01 program has progressed significantly, demonstrating the ability to elicit the desired biology in a non-human primate (NHP) model.
Key Highlights Include:
Mechanistic Validation: Non-Human Primate (NHP) data demonstrates AMP01 captures endogenous IL-15, redirects it to PD-1 positive T-cells, and induces T-cell activation and expansion in vivo.
Superior Potency: Our program AMP01 demonstrated greater potency at controlling tumor growth than Pembrolizumab in MC58 tumor engrafted mice.
Avoiding Toxicity: AMP01 avoids cytokine fusion technology, which mitigates toxicity, immunogenicity, narrow therapeutic window, and manufacturing challenges associated with traditional cytokine fusion approaches.
Leadership: David de Graaf, PhD (CEO), Surjit Dixit, PhD (CSO), Diana Hausman, MD (fractional CMO), Jean Jen, CPA, CA (fractional CFO), Ahmed Alkhateeb, PhD (fractional CBO), John Burke, PhD, (Chief Pharmacology Officer) and Ali Tehrani, PhD (Senior Advisor).
Financials: Previously closed a $12M seed round led by Amplitude Ventures, now preparing to raise $55M Series A round in 2026 to fund the lead AMP01 program through early Proof of Concept (POC).
Upcoming Milestones:
Generate POC data for AMP01 monotherapy by early 2028
Initially target indications such as gastric and Head and Neck cancer and pursue accelerated approval in areas of unmet need. Expand to broader indications through strategic partnerships.
2123 Frontiers Salon
An engaging evening of conversation, connection, advise shared over some amazing updates from the Biotech featured on the 2123 Frontiers platform, Reverb Therapeutics, Neuropeutics Inc, Aveta Biomics Inc and Switchback Therapeutics.
